study recruting: Dasatinib + Revlimid in Fludara resistant CLL

[Guest guest]

Greetings,

It appears that Dasatinib has modest activity in CLL, with reversible

toxicities. ... but I can't say that's the final word on it. Anyhow, the

following study will evaluate the combination of Dasatinib and Revlimid in

folks with purine-analog (such as fludarabine) resistent CLL.

I would think you'd test D+R in patients who have not benefited from R alone

? But that's just me. However, this is a feasiblity study ... a toe in

the water type - not meant to win marketing approval.

Anyhow, such combination studies are an indicator that drug sponsors are

jumping on the Revlimid bandwagon for CLL, hoping the mechanisms of their

candidate (Dasatinib being a Src and Abl kinase inhibitor) complements

Revlimid in some way.

~ Karl

==

A Phase I/II Study of Combination Dasatinib and Lenalidomide (Revlimid) in

Purine Analogue-Failed Chronic Lymphocytic Leukemia

Study details: http://clinicaltrials.gov/ct2/show/NCT00829647

* Preclinical: report on in-vitro activity of Dasatinib on CLL in cell

culture: http://www.ncbi.nlm.nih.gov/pubmed/18550857

* Clinical: Dasatinib Has [modest] Activity in Relapsed/Refractory Chronic

Lymphocytic Leukemia (CLL/SLL), a Phase II Trial

http://ash.confex.com/ash/2008/webprogram/Paper5762.html